Overview
Pharmaceutical Jet Mill
The size of drug particles is very important for drug absorption. After micronization, the active pharmaceutical ingredients become finer, more uniform, and the surface area increases. This increases the contact area between the drug and the digestive organs, making it easier to be absorbed by humans.
The jet mill can protect the bioactive ingredients and various heat-sensitive nutrients during low temperature grinding. In addition, the jet mill can maximize the utilization of APIs, reducing the loss of active ingredients during the production process.
D97<5μm
Fineness Range
GMP+
Compliant Design
0°C+
Cool Grinding
GMP Compliance
Engineered to meet the most stringent pharmaceutical manufacturing standards -- from high-potency API handling to sterile milling environments, fully aligned with FDA 21 CFR Part 211 and EMA GMP Annex 1/15.
High-Containment Design
Engineered for handling highly potent APIs (OEB 4/5).
The design ensures operator exposure to highly potent active pharmaceutical ingredients (HPAPIs) stays well below regulatory occupational exposure limits.
Cross-Contamination-Free
The internal surfaces are mirror-polished to Ra ≤ 0.4 µm, enabling validated batch-to-batch changeover.
The mill supports both fast manual disassembly for offline autoclaving and integrated Clean-in-Place protocols.
Integrated Isolator
The mill can be seamlessly integrated into isolators, RABS, or complete aseptic processing lines
This configuration satisfies the requirements for sterile injectable and inhalation-grade drug products.
Validation Support
Complete documentation package supports IQ/OQ/PQ and meets FDA 21 CFR Part 211, EU GMP Annex 1 & 15.
Standard deliverables include material traceability certificates, FAT/SAT protocols.
Features
Engineered for pharma-grade results.
Rapid CIP / Tool-Free Cleaning
Designed for high-frequency product changeovers, the system features a modular clamp-connection structure for complete, tool-free disassembly in minutes.
The Clean-in-Place capability, combined with mirror-polished surfaces, ensures thorough sanitation and prevents cross-contamination.
ATEX-Certified Protection
For combustible or solvent-wet APIs, the mill is available in a fully ATEX‑compliant configuration.
A closed‑loop inert gas system maintains oxygen below the limiting concentration, eliminating ignition risk. The design includes earth‑grounded product‑contact parts, and redundant oxygen monitoring.
Precise API Particle Control
Achieve consistent D50 targets from 1-10 μm with tight distribution for improved bioavailability and dosage uniformity.
Through grinding pressure and feed rare, you can fine-tune grinding parameters for repeatable results. This ensures every batch meets exact specifications.
Pharmaceutical API Trial Milling -- Full PSD Report Included
Submit your API or excipient sample for a no-obligation milling trial.
Specification
| Model | Chamber Ø (mm) | Capacity (kg/hr) | Air Consumption (m³/min) | Working Pressure (MPa) |
|---|---|---|---|---|
| AS50 | 50 | 0.05 - 0.5 | 0.6 - 0.9 | 0.6 - 1.0 |
| AS100 | 100 | 0.5 - 1 | 1.6 - 2.0 | 0.6 - 1.0 |
| AS150 | 150 | 2 - 10 | 2.5 - 3.5 | 0.6 - 1.0 |
| AS200 | 200 | 5 - 20 | 4.0 - 5.0 | 0.8 - 1.0 |
| AS300 | 300 | 10 - 80 | 6.5 - 7.0 | 0.8 - 1.0 |
| AS350 | 350 | 20 - 180 | 7.0 - 12.0 | 0.8 - 1.2 |
| AS450 | 450 | 40 - 400 | 10.0 - 12.0 | 0.8 - 1.2 |
| AS650 | 650 | 50 - 600 | 20.0 - 27.0 | 0.8 - 1.2 |
General Parameters
- Achievable D97 < 2 - 20 μm
- Contact Material Stainless steel 316L
- Surface Finish (Ra) ≤ 0.4 μm
- Certifications CE / GMP / ATEX
Download Full Technical Datasheet
Get the complete specifications, and performance data in one document. PDF · ~2MB
Applications
Pharmaceutical-Grade Powder Processing Solutions.
Inhalation Drug Delivery
Achieves the precise 1-5 μm particle size range critical for deep lung deposition in dry powder and metered-dose inhalers.
Narrow PSD ensures consistent aerodynamic performance and dose uniformity across batches.
Bioavailability Enhancement
Ideal for improving the solubility of poorly water-soluble drugs in oral solid dosages.
By increasing the total surface area through micronization, it enhances the dissolution rate and overall bioavailability.
HPAPI Processing
Designed for safe processing of HPAPIs such as oncology drugs and hormones, the system can be integrated into OEB 4/5 isolators.
It provides a physical barrier that protects both operators and product purity.
Injectables Manufacturing
Essential for the micronization of materials used in injectable suspensions.
The tool-free, CIP/SIP-ready design ensures that sterile environments are maintained, producing uniform particles.